<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190060</url>
  </required_header>
  <id_info>
    <org_study_id>CMMCHUT PIN 9197</org_study_id>
    <secondary_id>T0053/WTCRF</secondary_id>
    <nct_id>NCT00190060</nct_id>
  </id_info>
  <brief_title>Study of The Effects of Testosterone in Frail Elderly Men</brief_title>
  <official_title>Study of The Effects of Testosterone on Muscle Function, Physical Performance, Body Composition and Quality of Life in Frail Elderly Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Manchester University NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to determine the effects of testosterone on muscle function, mobility,
      activities of daily living and overall quality of life
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ageing-associated loss of muscle mass and strength is a major cause of physical frailty,
      disability, morbidity and dependency in the elderly. This is associated with increased falls,
      fractures, loss of mobility, restricted activities of daily living and increased utilisation
      of healthcare resources. It is well known that serum testosterone levels fall with advancing
      age and this may be an important cause for muscle wasting and weakness (sarcopenia).
      Testosterone replacement increases muscle mass and improves muscle strength in young
      hypogonadal men. In relatively healthy elderly men, some short-term studies have also shown
      that testosterone can improve muscle strength. The potential beneficial effects of
      testosterone supplementation on muscle strength and functional capacity of frail elderly men
      has so far not been studies and forms the basis of this research. We hypothesise that
      testosterone supplementation is an effective, safe and economic anabolic intervention in
      frail elderly men with low circulating testosterone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lower limb muscle strength at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Upper limb muscle strength at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total and regional lean body mass at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in physical performance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">262</enrollment>
  <condition>Frailty</condition>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transdermal testosterone gel (Testogel 1% )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched transdermal placebo gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal testosterone gel (Testogel 1% )</intervention_name>
    <description>Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Testogel 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched transdermal placebo gel</intervention_name>
    <description>Matched transdermal placebo gel, 50mg/d for 6 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Frail elderly men (as defined by Freid's criteria of frailty)

          -  Community - dwelling men aged 65 years and above

          -  Total testosterone ≤12.0 nmol/L or calculated free T≤0.25nmol/L

        Exclusion Criteria:

          -  Carcinoma of prostate

          -  Carcinoma of breast

          -  PSA &gt;4ng/mL

          -  Severe symptomatic benign prostatic hypertrophy (IPSS &gt;21)

          -  Active liver disease

          -  Renal impairment (serum creatinine &gt;180 mmol/L)

          -  Congestive heart failure

          -  Unstable ischaemic heart disease

          -  Polycythaemia

          -  Evidence of systemic disease which may affect muscle/joint function

          -  Moderate to severe peripheral vascular disease

          -  Moderate to severe chronic obstructive airways disease

          -  Alcohol consumption over 30 units per week

          -  Medications that interfere with sex steroid metabolism

          -  History of stroke causing persistent motor deficit

          -  Cognitive deficit

          -  Major psychiatric illness

          -  Hospital admission in the past 6 weeks

          -  Sleep apnoea
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Frederick CW Wu, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Manchester and Manchester Children's University Hospitals Trust &amp; The University of Manchester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Martin Connolly, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Manchester and Manchester Children's University Hospitals Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Professor JA Oldham, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Manchester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56.</citation>
    <PMID>11253156</PMID>
  </reference>
  <reference>
    <citation>Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab. 1984 Nov;59(5):955-62.</citation>
    <PMID>6480814</PMID>
  </reference>
  <reference>
    <citation>Clague JE, Wu FC, Horan MA. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Androl. 1999 Aug;22(4):261-5.</citation>
    <PMID>10442299</PMID>
  </reference>
  <reference>
    <citation>Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1172-81.</citation>
    <PMID>11701431</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>November 29, 2007</last_update_submitted>
  <last_update_submitted_qc>November 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2007</last_update_posted>
  <responsible_party>
    <name_title>Professor FCW Wu</name_title>
    <organization>Central Manchester and Manchester Children's University Hospitals NHS Trust</organization>
  </responsible_party>
  <keyword>Frailty</keyword>
  <keyword>Muscle strength</keyword>
  <keyword>Physical performance</keyword>
  <keyword>Bone mineral density</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

